NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP and cyclophosphamide in vivo

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 4, 1998, Pages 775-779

  Papadopoulou, Maria V ^a   Ji, Ming ^a   Bloomer, William D ^a  

^a Evanston Northwestern Healthcare ^*  (United States)

Author keywords

Bioreductive drugs; Chemotherapeutic agents; NLCQ 1; Potentiation

Indexed keywords

4 [3 (2 NITROIMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIN; MELPHALAN; NITROIMIDAZOLE DERIVATIVE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW TOXICITY; BREAST CARCINOMA; CANCER GROWTH; CANCER SIZE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; HYPOXIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE OXYGENATION; TUMOR GROWTH;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; CYCLOPHOSPHAMIDE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; MALE; MELPHALAN; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; PRODRUGS;

EID: 0031773145     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00333-2     Document Type: Conference Paper

References (27)

1. Hockel M., Schlenger K., Mitze M., et al. Hypoxia and radiation response in human tumors. Seminars in Radiat Oncol. 6:1996;3-9.
2. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 26:1993;45-50.
3. Siemann D.W. Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys. 10:1984;1585-1594.
4. Grau C., Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol. 13:1988;301-309.
5. Kennedy K.A. Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des. 2:1987;181-194.
6. Sartorelli A.C. Therapeutic attack of hypoxic cells of solid tumors presidential address . Cancer Res. 48:1988;775-778.
7. Papadopoulou M.V., Mainwaring A., Bloomer W.D. Potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea's toxicity in vitro by two new bioreductive agents. Jpn J Cancer Res. 83:1992;907-913.
8. Papadopoulou M.V., Miller A., Seskey T., et al. Potentiation of antineoplastic drugs in vitro and in vivo by intercalating bioreductive agents. Radiat Oncol Invest. 1:1993;206-217.
9. Papadopoulou M.V., Ji M., Bloomer W.D. THNLA-1 A DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo . In Vivo. 10:1996;49-58.
10. Papadopoulou M.V., Ji M., Bloomer W.D. THNLA-1 as radio/chemosensitizer of EMT6 tumors in mice. Br J Cancer. 74:(Suppl. XXVII):1996;S267-S270.
11. Papadopoulou M.V., Ji M., Rao M.K., Bloomer W.D. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1) A novel DNA-affinic bioreductive agent as chemosensitizer I . Oncol Res. 9:1997;249-257.
12. Murray D., Meyn R.E. Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo. Br J Cancer. 47:1983;195-203.
13. Holden S.A., Teicher B.A., Ara G., et al. Enhancement of alkylating agent activity by SR-4233 in FSaIIC Murine Fibrosarcoma. J Nat Cancer Inst. 84:1992;187-193.
14. Dorie M.J., Brown J.M. Tumor-specific, schedule-dependent interaction between Tirapazamine (SR4233) and Cisplatin. Cancer Res. 53:1993;4633-4636.
15. Siemann D.W., Mulcahy R.T. Sensitization of cancer chemotherapeutic agents by nitroheterocyclics. Biochem Pharmacol. 35:1986;111-115.
16. Siemann D.W., Sutherland R.M. Potentiation of alkylating chemotherapy by dual function nitrofurans in multicell spheroids and solid tumors. Radiother Oncol. 24:1992;239-245.
17. Papadopoulou M.V., Rosenzweig H.S., Doddi M., Bloomer W.D. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]-1,2,3,4-tetrahydroacridine hydrochloride A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1 . Oncol Res. 6:1994;439-448.
18. Papadopoulou M.V., Ji M., Doddi M., Bloomer W.D. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1) A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer . Oncol Res. 8:1996;425-434.
19. Hay M.P., Wilson W.R., Moselen J.W., et al. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides A new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers . J Med Chem. 37:1994;381-391.
20. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound: Cytotoxicity and reduction studies. Proceedings of the Second International Conference on Redox Processes and Cancer: Molecular Biology and Therapeutics, April 7-10, 1997. Alberta, Canada; 1997.
21. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1): A novel bioreductive agent with enhanced hypoxic selectivity. Proceedings of the 45th Annual Meeting of the Radiation Research Society and 16th Annual Meeting of the North American Hyperthermia Society, May 3-7, 1997. Providence, RI; 1997.
22. Rockwell S.C., Kallman R.F., Fajardo L.F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst. 49:1972;735-749.
23. Teicher B.A., Rose C.M. Perfluorochemical emulsions can increase tumor radiosensitivity. Science. 223:1984;934-936.
24. Herman T.S., Teicher B.A., Holden S.A., et al. Addition of 2-nitroimidazole radiosensitizers to cis-diamminedichloro-platinum (II) with radiation and with or without hyperthermia in the murine FSaIIC fibrosarcoma. Cancer Res. 50:1990;2734-2740.
25. Siemann D.W., Allalunis-Turner M.J. Potentiation of combination chemotherapy by nitroheterocyclics. Int J Radiat Oncol Biol Phys. 16:1988;973-976.
26. Papadopoulou M.V., Ji M., Rao M.K., et al. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1) A novel DNA-affinic bioreductive agent as chemosensitizer: Mechanistic studies. II . Oncol Res. 10:1998;163-173.
27. Papadopoulou MV, Ji M, Rao MK; et al. Mechanistic studies regarding the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro. Proceedings of the 87th AACR Annual Meeting, April 20-24, 1996. Washington, DC. 1996;37:355-356.